Serum level of cartilage oligomeric matrix protein (COMP) in equine osteoarthritis.
Authors: Misumi K, Vilim V, Hatazoe T, Murata T, Fujiki M, Oka T, Sakamoto H, Carter S D
Journal: Equine veterinary journal
Summary
# Editorial Summary: COMP as a Biomarker for Equine Joint Disease Cartilage oligomeric matrix protein (COMP) has emerged as a promising biochemical marker for detecting joint pathology in horses. Misumi and colleagues compared serum and synovial fluid concentrations of COMP and keratan sulphate in 38 clinically normal horses against 40 with aseptic joint disease using inhibition ELISA, measuring both serum samples from all animals and synovial fluid from 53 horses. Horses with joint disease demonstrated significantly lower serum COMP concentrations (10.7 µg/ml versus 14.8 µg/ml in controls, P<0.02) and reduced keratan sulphate levels, though notably, serum COMP levels correlated strongly with synovial fluid COMP (r=0.52, P<0.001) whilst KS did not. For practitioners, this work suggests serum COMP testing could provide a more specific non-invasive diagnostic window into cartilage degradation than previously available markers, potentially enabling earlier detection of joint disease before clinical signs become apparent or enabling more objective monitoring of osteoarthritic progression.
Read the full abstract on PubMed
Practical Takeaways
- •Serum COMP testing could provide a specific diagnostic tool for identifying joint disease in horses without requiring joint aspiration
- •Lower serum COMP levels are associated with aseptic joint pathology, making it potentially useful for early detection of osteoarthritis
- •The correlation between serum and synovial fluid COMP supports use of blood sampling as a non-invasive alternative to joint fluid analysis for monitoring joint health
Key Findings
- •Serum COMP concentration was significantly lower in horses with aseptic joint disease (10.7 ± 7.4 µg/ml) compared to controls (14.8 ± 7.8 µg/ml, P<0.02)
- •Keratan sulphate levels were also significantly reduced in joint disease horses (180.5 ± 61.8 ng/ml) versus controls (237.1 ± 116.1 ng/ml, P<0.01)
- •Significant correlation existed between serum and synovial fluid COMP levels (r=0.52, P<0.001), but not for keratan sulphate
- •Serum COMP concentration may be a more specific biomarker for equine joint disease than previously described markers